adenocarcinoma who were former light or never smokers (the key clinical characteristics associated with response to EGFR TKI and presence of EGFR mutations) to receive either gefitinib or the combination of carboplatin and paclitaxel as first-line treatment. 7
Search Results
Second-Generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Lung Cancers
Helena A. Yu and Gregory J. Riely
Clinical Sequencing Contributes to a BRCA-Associated Cancer Rediagnosis That Guides an Effective Therapeutic Course
Jocelyn S. Chapman, Saurabh Asthana, Lindsay Cade, Matthew T. Chang, Zhen Wang, Charles J. Zaloudek, Stefanie Ueda, Eric A. Collisson, and Barry S. Taylor
-bound paclitaxel therapy. 8 Results of this CT showed evolving findings, including ascites with peritoneal thickening, a complex 6.1-cm right adnexal lesion, and the absence of a discrete pancreatic mass, which was reinterpreted as a lymph node conglomerate
Beyond Median Overall Survival: Estimating Trends for Multiple Survival Scenarios in Patients With Metastatic Esophagogastric Cancer
Marieke Pape, Steven C. Kuijper, Pauline A.J. Vissers, Laurens V. Beerepoot, Geert-Jan Creemers, Hanneke W.M. van Laarhoven, and Rob H.A. Verhoeven
improvements seen in the ToGA trial (2011) for trastuzumab and the RAINBOW trial (2016) for paclitaxel and ramucirumab. 4 , 8 Among patients with gastric cancer receiving systemic therapy, the survival benefits were largest in the best-case (p10; 4.7 months
Modification and Implementation of NCCN Guidelines™ on Breast Cancer in the Middle East and North Africa Region
Omalkhair Abulkhair, Nagi Saghir, Lobna Sedky, Ahmed Saadedin, Heba Elzahwary, Neelam Siddiqui, Mervat Al Saleh, Fady Geara, Nuha Birido, Nadia Al-Eissa, Sana Al Sukhun, Huda Abdulkareem, Menar Mohamed Ayoub, Fawaz Deirawan, Salah Fayaz, Alaa Kandil, Sami Khatib, Mufid El-Mistiri, Dorria Salem, El Siah Hassan Sayd, Mohammed Jaloudi, Mohammad Jahanzeb, and William I. Gradishar
pathological complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer . J Clin Oncol 2005 ; 23
NCCN Guidelines Insights: Small Cell Lung Cancer, Version 2.2018
Gregory P. Kalemkerian, Billy W. Loo Jr, Wallace Akerley, Albert Attia, Michael Bassetti, Yanis Boumber, Roy Decker, M. Chris Dobelbower, Afshin Dowlati, Robert J. Downey, Charles Florsheim, Apar Kishor P. Ganti, John C. Grecula, Matthew A. Gubens, Christine L. Hann, James A. Hayman, Rebecca Suk Heist, Marianna Koczywas, Robert E. Merritt, Nisha Mohindra, Julian Molina, Cesar A. Moran, Daniel Morgensztern, Saraswati Pokharel, David C. Portnoy, Deborah Rhodes, Chad Rusthoven, Jacob Sands, Rafael Santana-Davila, Charles C. Williams Jr, Karin G. Hoffmann, and Miranda Hughes
intravenously in patients with recurrent SCLC. 29 – 31 Based on phase II trials, a number of other agents have been recommended as options for subsequent systemic therapy in patients with relapsed disease, including irinotecan, paclitaxel, docetaxel
A US Registry–Based Assessment of Use and Impact of Chemotherapy in Stage I HER2-Positive Breast Cancer
Benjamin M. Parsons, Dipesh Uprety, Angela L. Smith, Andrew J. Borgert, and Leah L. Dietrich
.5%–97.5%]) are very similar to those from a phase II, prospective, nonrandomized study of weekly adjuvant paclitaxel in combination with trastuzumab for 12 weeks, followed by maintenance trastuzumab for 1 year in patients with node-negative, HER2-positive breast
Cost-Effectiveness of Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer
Bin Wu and Lizheng Shi
shown promising results in early trials. 31 , 32 However, there is a dearth of information regarding the economic outcome of maintenance treatments for MPC. Although 2 previous economic analyses have shown that a chemotherapy regimen containing nab-paclitaxel
Biologics in Cervical Cancer Therapy
Lyndsay J. Willmott, Daniele A. Sumner, and Bradley J. Monk
patients to 4 arms, 2 of which include combination chemotherapeutic regimens that were found to have benefit in the study population (paclitaxel/cisplatin vs. paclitaxel/topotecan) compared with these regimens plus bevacizumab ( Table 1 ). All medication
Adjuvant Treatment of Early Ovarian Clear Cell Carcinoma: A Population-Based Study of Whole Abdominal Versus Pelvic Nodal Radiotherapy
Soumyajit Roy, Paul Hoskins, Anna Tinker, Harinder Brar, Gale Bowering, and Gaurav Bahl
). Since 2000, standard provincial treatment in chemo-WART group consisted of 3 cycles of carboplatin (area under the curve [AUC], 5–6) and paclitaxel (175 mg/m 2 ) every 3 to 4 weeks followed by abdominopelvic irradiation. RT was initiated 3 to 4 weeks
Fertility Preservation in Patients With Breast Cancer: Necessity, Methods, and Safety
Adrienne G. Waks and Ann H. Partridge
-mutated patients. 17 Of relevance to HER2-positive patients, available data suggest no significant additive impact on amenorrhea from 1 year of trastuzumab therapy, 12 and the CRA rate associated with paclitaxel/trastuzumab (TH) for women with small HER
